Advertisement
Advertisement

MIRM

MIRM logo

Mirum Pharmaceuticals, Inc. Common Stock

103.06
USD
Sponsored
+2.21
+2.19%
Jan 29, 16:00 UTC -5
Closed
exchange

After-Market

102.96

-0.10
-0.09%

MIRM Earnings Reports

Positive Surprise Ratio

MIRM beat 13 of 26 last estimates.

50%

Next Report

Date of Next Report
Feb 24, 2026
Estimate for Q4 25 (Revenue/ EPS)
$142.98M
/
$0.00
Implied change from Q3 25 (Revenue/ EPS)
+7.49%
/
-100.00%
Implied change from Q4 24 (Revenue/ EPS)
+43.82%
/
-100.00%

Mirum Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Nov 04, 2025, MIRM reported earnings of 0.05 USD per share (EPS) for Q3 25, beating the estimate of -0.16 USD, resulting in a 129.76% surprise. Revenue reached 133.01 million, compared to an expected 132.68 million, with a 0.25% difference. The market reacted with a -1.24% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 142.98 million USD, implying an decrease of -100.00% EPS, and increase of 7.49% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Mirum Pharmaceuticals, Inc. Common Stock reported EPS of $0.05, beating estimates by 129.76%, and revenue of $133.01M, 0.25% above expectations.
The stock price moved down -1.24%, changed from $70.97 before the earnings release to $70.09 the day after.
The next earning report is scheduled for Feb 24, 2026.
Based on 12 analysts, Mirum Pharmaceuticals, Inc. Common Stock is expected to report EPS of -- and revenue of $142.98M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement